.
Once PrP
Sc is present in an individual (owing to spontaneous conformational conversion or to infection), it is capable of recruiting PrP C and converting it to the disease form. Definitive proof of the proteinonly hypothesis, which states that prions are composed solely of PrP Sc , calls for the generation of infectious prions in the laboratory -a process that has proved elusive for decades. Artificially generated prions (synthetic prions) were initially reported several years ago 2 , but these preparations had low infectious titres and only affected a single line of transgenic mice that overexpressed an amino-terminally truncated wild-type PrP corresponding to the protease-resistant core of PrP Sc . Although these mice do not spontaneously generate prions 3 , the high expression and truncated sequence of the transgene were thought to render these mice more susceptible to synthetic-prion infection. Here, we discuss several recent advances in the generation of synthetic prions, including reports of high-titre preparations 4 ; the infection of additional experimental animals, including wild-type mice and Syrian hamsters [4] [5] [6] [7] [8] ; the ability to control prion strain properties by adjusting the conditions used for prion formation 5 ; and the description of novel synthetic prion strains that mimic rare forms of the disease 3 (TABLE 1) .
Prion strains
The existence of prion strains, which are isolates that generate distinct phenotypes in identical hosts, was an enigmatic discovery for many years 9 . Because prions are composed of only protein and replicate using the PrP C substrate that is present in the host, differences in prion strains cannot be attributed to genetic variability (which accounts for the existence of viral strains). To explain this phenomenon, a hypothesis was proposed stating that prion strains result from conformational variability -that is, PrP can assume several different, self-propagating conformations, each of which accounts for a distinct prion strain 10 . Analysis of prions that were isolated from infected animals with different phenotypes showed that the prions had distinct biochemical properties, which provided indirect evidence for this hypothesis [11] [12] [13] . Although direct evidence for the conformational basis of mammalian prion strains has been difficult to obtain, Saccharomyces cerevisiae proteins with self-replicating conformations, known as yeast prions 14, 15 , have contributed significantly to our understanding of the molecular basis of prion strains. One such protein is the translation termination factor Sup35, which in its prion state suppresses phenotypes that are caused by nonsense mutations. 16 . The propagation rates of yeast prions are related to the strength of the phenotype, as weaker prions are more frequently lost during cell division 17, 18 . The propagation rates for these [PSI + ] strains were inversely correlated to their conformational stabilities (based on thermal denaturation) 16 , a finding that was later extended to mammalian prion strains 13 . Although discoveries with yeast prions may guide studies of mammalian prions, it is important to note that there are substantial differences between the two systems. Yeast prions do not cause disease and, therefore, cannot teach us about the pathogenesis of prion diseases. On the cellular level, yeast prions propagate by cell division, whereas mammalian prions spread between quiescent, terminally differentiated neurons in the brain. Furthermore, yeast prions propagate on a molecular level by a simple amyloid growth mechanism, in which monomers are added to the growing end of the fibre 19 , allowing for relevant insights from purely in vitro models 20 . By contrast, mammalian prions are not necessarily composed of amyloid, although most are competent to form amyloid 21 and to seed amyloid growth 22 .
Cell-free systems for creating prions
The development of cell-free in vitro models for mammalian prion propagation lags behind analogous systems in S. cerevisiae. 
. Although sonication introduces a series of problems, such as heterogeneous protein denaturation and high well-to-well variability in the generation of PrP Sc , PMCA is currently the only cell-free technique that converts PrP C into an infectious form with substantial yields.
Several important discoveries laid the foundation for recent advances in the creation of prions in the laboratory. Transgenic mice expressing PrP with a Pro101Leu mutation (which corresponds to the mutation that causes Gerstmann-Sträussler-Scheinker disease in humans) developed neurological dysfunction and exhibited brain lesions typical of prion disease, with disease onset times that were dependent on the level of transgene expression 26 . A 55-mer peptide -residues 89-143 of PrP (PrP(89-143) containing the Pro101Leu mutation and folded into a β-sheet-rich conformation -hastened disease onset when inoculated into young mice that expressed low levels of the PrP(Pro101Leu) transgene 27, 28 . In later work, Tg9949 mice, which overexpress truncated mouse PrP (PrP(89-231)) and are not genetically predisposed to develop prion disease, were infected with recombinant PrP(89-230) that was folded into an amyloid conformation 2 . The prion strain recovered from the brains of these mice was denoted MoSP1 and was transmissible in wild-type mice by serial passage 2 . MoSP1 was easily distinguished from naturally occurring prions owing to its high conformational stability 29 . During two subsequent rounds of serial passage, the incubation period (measured from inoculation to onset of neurological dysfunction) of MoSP1 isolates in Tg9949 mice decreased from >500 days to 177 days 13 . New prion strains from amyloid fibres Biochemical analysis of prions that were obtained from infected animals has provided some insight into the structural variations that make up different strains. These variations include differences in glycosylation patterns, extent of protease resistance, electrophoretic mobility of proteolytic fragments and conformational stability 11, 30 . However, the ability to modulate prion strain phenotypes experimentally by altering the conformation of PrP has only recently been demonstrated: recombinant PrP folded into distinct amyloid conformations gave rise to distinguishable prion strains, with incubation periods that were dependent on the conformational stability of the recombinant PrP amyloid 5 . By altering the conditions that were used to refold recombinant PrP, amyloids with different conformational stabilities were generated. These amyloids were then inoculated into mice that overexpressed full-length PrP at levels that were fourfold greater than wild-type levels. This resulted in prion strains with incubation periods and conformational stabilities that were correlated to the stability of the amyloid fibres used to inoculate the mice (FIG. 2) . The failure to infect wild-type mice directly with these preparations indicates that unidentified properties, in addition to conformational stability, modulate infectivity and incubation period. Conflicting results using hamster BSA, bovine serum albumin; PrP, prion protein; PrP C , cellular PrP; recPrP, recombinant PrP; SSLOW, synthetic strain leading to overweight. *n is the number of independent preparations that were tested in the bioassay and resulted in infectivity. ‡ The PrP(Pro101Leu) peptide was deemed to have accelerated spontaneous disease rather than initiated a new prion strain. § The determination of the incubation period was complicated by the late-onset neurological dysfunction that occurs in Tg9949 mice.
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A detailed characterization of MoSP2 is described in REF. 3. prion strains with conformational stabilities that cover a much narrower range, compared to the studies using synthetic prions, also support this notion 31 . Nonetheless, the direct demonstration of the conformational basis of prion strain diversity provides further evidence that synthetic prions originate from the recombinant amyloid preparations, and not from the host or from contamination. If prions were arising spontaneously in the host, one would expect the strain properties to be independent of the amyloid properties. In addition, exhaustive negative controls, including inoculation of the host mice with control solutions, biochemical and neuropathological analysis of age-matched controls and serial passage of aged brains from the host mice, exclude spontaneous prion generation and contamination 5 . Although these studies clearly established that distinct conformations of synthetic prions can account for different phenotypes, they did not elucidate the mechanisms of infectivity. Some amyloid conformations were infectious, whereas others were not 5 . Thus, how infectivity is enciphered in prions remains to be established. 32 . This observation has led to the idea that protease resistance equates with prion infectivity and pathogenesis. However, many naturally occurring prion strains also contain PrP Sc in a conformation that is sensitive to protease digestion (sPrP Sc ) 30 . The synthetic sPrP Sc- strains that were generated demonstrate that sPrP Sc is transmissible and pathogenic and can occur as a distinct entity from rPrP . This finding suggests that the protease resistance of prion strains is determined by one or more subtle conformational differences, some of which may occur stochastically.
When amyloid fibres that are formed from recombinant hamster PrP were exposed to heat in the presence of brain homogenate or albumin, this led to the generation of a novel prion strain, which was named synthetic strain leading to overweight (SSLOW) 6 . Hamsters that were inoculated with amyloid fibres prepared in this way did not show symptoms of disease during the 661 days of observation following inoculation, but were found to have low levels of PrP Sc in their brains upon termination of the experiment. Serial transmission of this prion strain caused disease in >480 days. The conformational stability of SSLOW is comparable to naturally occurring prion strains. However, the disease phenotype reported was unusual, in that it included weight gain and Nature Reviews | Microbiology an unusually slow disease progression. Given the biochemical similarities between SSLOW and naturally occurring prions, it would be interesting to determine the conformational basis of this unusual strain phenotype.
New prion strains from sonication
A central issue in the generation of prions from recombinant protein has been the apparently low titres of infectivity 33 , which result in long incubation times and often the inability to infect wild-type animals directly. If long incubation times do, in fact, result from low titres, this implies that synthetic-prion preparations are heterogeneous mixtures containing many different conformations (which limits their usefulness for determining the structure of PrP Sc ). Alternatively, long incubation times may indicate that amyloid fibres require maturation or further adaptation of their confor mation in order to become fully infectious.
Several laboratories have succeeded in creating infectious prions by PMCA 4, 7, 8 . The initial report of the spontaneous generation of infectivity came in the form of the unexpected amplification of prions in negative controls during studies that aimed to identify the minimal components necessary for prion amplification in vitro 8 . Amplification required the addition of polyanions to PrP C , which was also accompanied by co-purified lipids. These results were verified by repeating the experiment in a laboratory that had never been used for prion research, thus reducing the potential for contamination. It was later shown that prions can be generated in a similar fashion using brain homogenate as the substrate (rather than minimal components) and that this newly created prion strain was distinct from a commonly used laboratory strain 7 . Prions created in these studies using either PrP C or normal brain homogenate had titres that were sufficient to infect hamsters with incubation periods of 113-168 days, whereas naturally occurring hamster prion strains have incubation periods of 60-300 days 30, 34 . The synthesis of highly infectious prions from recombinant PrP has recently been reported using PMCA in the presence of lipids and RNA 4 . The infectivity of these preparations was comparable to that of naturally occurring strains, implying that the authors have achieved a level of purity several orders of magnitude higher than previously reported. Such high titres can be rapidly detected by bioassay (that is, inoculation of preparations into experimental animals to determine infectivity), so the robustness and reproducibility of these findings should soon become apparent. Despite this remarkable report, the possibility of contamination in PMCA cannot be eliminated -especially given reports of a billion-fold amplification of prion titres using PMCA 25 -and no convincing control has been devised. Even if this finding was attributable to contamination of the starting materials, the ability to amplify prions efficiently using recombinant protein is a significant breakthrough, as it may enable the use of labelled recombinant protein for structural studies.
In related work, recombinant PrP (rather than PrP C from brain homogenates) has been used as the substrate in the PMCA reaction, using purified PrP Sc seed that was obtained from brain homogenate 35 . This study showed that polyanions and lipids are not required for prion amplification, although the presence of trace quantities of such cofactors in the brainderived seed was not ruled out. The attack rate (that is, the fraction of inoculated animals that developed prion disease) in bioassays was consistent with there being low titres in these preparations, rather than a prion strain with a long incubation period. On serial passage, the incubation periods and biochemistry of these amplified prions were consistent with those of the naturally derived strain that was used as the seed, although the pattern of brain lesions indicated some differences. If a novel prion strain was in fact created, this argues that prolonged sonication can alter the conformation of PrP Sc . Despite these exciting results, some caveats should be noted about the PMCA approach. This technique results in uneven amplification of prions -from well to well and from experiment to experiment -which produces great variability 36 and prevents the resulting data from being quantified. It is well documented that sonication causes an uneven distribution of energy, resulting in cavitation and associated high temperatures 37 , as well as the generation of free radicals 38 . Protein conformation is sensitive to temperature denaturation, and free radicals may covalently alter proteins. Both cavitation and free-radical modification of proteins are stochastic processes and inherently difficult to control, potentially explaining the variability observed in PMCA experiments. By contrast, the denaturing reagents urea and guanidine, which are used in other techniques that produce synthetic prions 2, 3, 5 , result in comparatively even and well-defined denaturation of protein throughout the solution. In some cases, sonication initiates amyloid formation with proteins that are usually monomeric 39 , which indicates denaturation. Furthermore, such alterations in protein conformation may result in the degradation of the protein 40 . It is noteworthy that the durations of sonication that are used for PMCA greatly exceed those used in the production of recombinant protein, often by a factor of over 100. Degradation and denaturation may thus limit the usefulness of products produced by PMCA for structural studies.
Other protein-misfolding diseases Recent findings implicate a prion-like spread of misfolded proteins in Alzheimer's disease 41 and Parkinson's disease 42, 43 , following on from earlier suggestions that the amyloid formed in Alzheimer's disease might be the cause of this disorder [44] [45] [46] [47] . The ability to model disease states using synthetic peptides and recombinant proteins refolded into pathogenic conformations can shed light on the molecular mechanisms involved in these and other diseases. For example, systemic amyloidosis caused by serum amyloid A (SAA) may also be transmitted by a prion-like mechanism 48, 49 , and amyloid fibres composed of synthetic peptides corresponding to fragments of the SAA protein can accelerate the disease process 50 . Brain extracts containing misfolded Aβ peptides accelerated disease in transgenic mouse models of Alzheimer's disease, in which the mice overexpressed diseaserelated mutations in the amyloid precursor protein. However, the synthetic peptides Aβ and Aβ , which mimic the short peptides found in Alzheimer's disease and were aged to allow time for formation of fibrils, failed to accelerate disease in the same mouse model 41 . Notably, synthetic Aβ peptides prepared in a similar manner have been shown to be neurotoxic 51 . These findings suggest that different conformations mediate neurotoxicity and self-propagation. In fact, earlier work with synthetic Aβ peptides suggested a neurotoxic mechanism that involved the initiation of microtubule-associated protein tau misfolding within the cell 52 . The prion-like propagation of extracellular proteins such as Aβ and SAA is not entirely unexpected, given the ability of these proteins to interact with homologous proteins without having to cross a cell membrane; however, recent findings suggest that this may be the case for intracellular proteins as well. Intracellular aggregates had previously been thought to arise in individual cells during stochastic nucleation events 53 . Recently, aggregates of several proteins, including tau 54 , α-synuclein 55 and polyglutamine 56, 57 , have been shown to pass from the extracellular space into the cell or from one cell to another. Aggregates formed of truncated recombinant tau were shown to enter cells and seed the polymerization of endogenous tau. Furthermore, these tau aggregates were also shown to pass from cell to cell in culture 54 . It seems plausible that aggregates are released into the extra cellular space after a cell dies, and that these aggregates then break apart and infect other cells.
In the case of α-synuclein, the overexpression and misfolding of which is associated with Parkinson's disease, endocytosis seems to have an important role in its prion-like spread. In cell culture, the formation of fibrils of recombinant α-synuclein is required for the protein to enter the cell. Fibrils composed of recombinant α-synuclein are internalized by endocytosis 55 , resulting in cell death 58 , again releasing toxic aggregates into the extracellular space that infect other cells. Like tau, α-synuclein has also been shown to pass from cell to cell in culture 59 . The prion-like spread of protein aggregates has been independently demonstrated for polyglutamine peptides, which represent a key sequence motif in the huntingtin protein.
Additional polyglutamine repeats in huntingtin cause Huntington's disease; generally, the number of repeats inversely correlates with the age of onset (the age at which the person manifests the first clinical signs of disease). Cells have been shown to take up aggregates of chemically synthesized polyglutamine peptides, resulting in death when these peptides are localized to the nucleus 56 . Following uptake, aggregates initiate the conformational conversion of endogenous polyglutamine-containing proteins, resulting in persistent protein misfolding 57 . The role of protein misfolding in Huntington's disease has been controversial 60 ; these recent results suggest that the mechanism of conformation-dependent toxicity may be more complex than had been appreciated previously, as it is now apparent that the mechanism may involve both spontaneous misfolding within cells and cell-to-cell transmission of misfolded proteins.
Looking forward
Although accumulating evidence has established that the misprocessing of specific proteins occurs in the pathogenesis of many disorders, including Alzheimer's, Parkinson's and Huntington's as well as the tauopathies and prion diseases described above, the elucidation of atomic-level structures for these misfolded proteins has been nearly impossible, except in the case of short-to intermediate-length peptides 61 . Major obstacles include insolubility, conformational heterogeneity and difficulty in assembling misfolded proteins into crystals. Some structural insights have been achieved for fungal prions through solid-state NMR (ssNMR) 62 and hydrogenexchange coupled with NMR (HXNMR) 63 . However, these observations depend on obtaining a high yield of the fungal prion proteins in their active state. Studies employing X-ray fibre diffraction, a technique that has yielded only low-resolution structural information, suggest that amyloid fibre preparations containing synthetic prions form different structural assemblies compared to naturally occurring prions 64 , implying that the process for converting recombinant PrP into a pathogenic form by amyloid formation will need to be improved before ssNMR or HXNMR can be meaningfully applied. Whether the high-titre prions generated from recombinant PrP using sonication 4 are of sufficient quality and quantity to allow for structural determination remains to be seen. Structural determinations of aberrantly folded proteins should provide mechanistic insights into propagation and pathogenicity.
Like fungal prions 65 , mammalian prions probably replicate with the assistance of as-yet-unknown auxiliary factors 66 . Experiments using PMCA suggest that polyanions and lipids may facilitate conversion in a nonspecific manner 4, 8 . Undoubtedly, the increasing reliability of in vitro models should shed light on the effect of cofactors on the conversion process.
The generation of prion infectivity from defined components in the laboratory is an objective as ambitious and complex as synthesizing a virus from nucleic acid 67 or replicating DNA outside of the cellular context 68 . Although the foundations of this field were established several years ago 2, 27 , recent advances have improved the efficiency with which prions can be made 4 and our ability to modulate synthetic-prion conformation 5 . These advances provide the strongest argument to date that the infectivity of prions resides only in their proteinaceous component, evidence that should satisfy any reasonable sceptic. The ability to generate high-quality preparations of prions from recombinant protein and to control their properties should yield unprecedented insights into the structural and mechanistic biology of prions. Such insights should bring us closer to a cure for Creutzfeldt-Jakob disease and other neurodegenerative disorders.
Glossary

Aβ
A short peptide that is cleaved from amyloid precursor protein and forms the amyloid plaques that are found in Alzheimer's disease.
α-synuclein
A protein expressed primarily in neurons and can aggregate to form Lewy bodies (abnormal protein aggregates inside nerve cells), which are found in Parkinson's disease and dementia with Lewy bodies.
Gerstmann-Sträussler-Scheinker syndrome
A genetic neurodegenerative disease in humans that is caused by mutations in the PRNP gene, which encodes the prion protein (PrP).
Huntingtin
A protein that may have a role in microtubule-mediated transport or vesicle function. The expanded polyglutamine repeats within huntingtin cause Huntington's disease.
Microtubule-associated protein tau
A protein that is expressed primarily in neurons and promotes microtubule assembly and stability.
Prion protein (PrP) . A glycosyl phosphatidylinositol-anchored membrane protein that is expressed in many organs and is required for the development of prion diseases. The normal function of PrP is unknown.
Systemic amyloidosis
A disease in which amyloid is deposited in various organs outside the central nervous system.
Synthetic prions
Infectious proteins that can be created from minimal components in the laboratory and demonstrate infectivity in living organisms.
Tauopathies
Neurodegenerative diseases that are caused by the misprocessing and aggregation of microtubule-associated protein tau, which results in neurofibrillary tangles, paired helical filaments and/or Pick bodies (silver-staining, spherical protein aggregations) in the brain.
